Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 31;4(3):e1311827.
doi: 10.1080/23723556.2017.1311827. eCollection 2017.

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Derek J Erstad  1 , Andrew M Tager  2 , Yujin Hoshida  3 , Bryan C Fuchs  1
Affiliations

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Derek J Erstad et al. Mol Cell Oncol. .

Abstract

Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

Keywords: ATX; HCC; LPA; LPAR1; NASH; chemoprevention; cirrhosis; fibrosis; hepatocellular carcinoma; non-alcoholic steatohepatitis.

PubMed Disclaimer

References

    1. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology. 2014; 60(5):1767-75; PMID:24839253; https://doi.org/10.1002/hep.27222 - DOI - PMC - PubMed
    1. Kudo M. Immune checkpoint inhibition in Hepatocellular Carcinoma: Basics and ongoing clinical trials. Oncology. 2017; 92 Suppl 1:50-62; PMID:28147363; https://doi.org/10.1159/000451016 - DOI - PubMed
    1. Hoshida Y, Fuchs BC, Tanabe KK. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets. 2012; 12(9):1129-59; PMID:22873223; https://doi.org/CCDT-EPUB-20120803-4 [pii] - PMC - PubMed
    1. Bain G, Shannon KE, Huang F, Darlington J, Goulet L, Prodanovich P, Ma GL, Santini AM, Stein AJ, Lonergan D, et al.. Selective inhibition of Autotaxin is efficacious in mouse models of liver Fibrosis. J Pharmacol Exp Ther. 2017; 360(1):1-13; PMID:27754931; https://doi.org/10.1124/jpet.116.237156 - DOI - PubMed
    1. Aikawa S, Hashimoto T, Kano K, Aoki J. Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem. 2015; 157(2):81-9; PMID:25500504; https://doi.org/10.1093/jb/mvu077 - DOI - PubMed

LinkOut - more resources